Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Loreen Natusch Bufe

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Oncoimmunology|November 6, 2025
Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinomaFranziska Baenke, Antonia Stammberger, Ulrich Sommer, et al.
Annals of Surgical Oncology|May 2, 2026
Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer SurgeryLoreen Natusch Bufe, Marie Crede, David Digomann, et al.
JCI Insight|December 9, 2025
Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancerMax Heiduk, Carolin Beer, Sarah Cronjaeger, et al.
Iscience|December 1, 2025
Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancerDavid Digomann, Charlotte Reiche, Antonia Stammberger, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Oncoimmunology|November 6, 2025
Intratumoral regulatory T cells are associated with treatment response to neoadjuvant chemotherapy and prognosis in gastroesophageal adenocarcinomaFranziska Baenke, Antonia Stammberger, Ulrich Sommer, et al.
Annals of Surgical Oncology|May 2, 2026
Combined Preoperative Risk Score Including sCD40, Leukocytes, and BMI Predicts Pancreas-Specific Complications After Pancreatic Cancer SurgeryLoreen Natusch Bufe, Marie Crede, David Digomann, et al.
JCI Insight|December 9, 2025
Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancerMax Heiduk, Carolin Beer, Sarah Cronjaeger, et al.
Iscience|December 1, 2025
Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancerDavid Digomann, Charlotte Reiche, Antonia Stammberger, et al.
Pageof 1